Patents Issued in January 7, 2020
-
Patent number: 10526271Abstract: Half salts of certain synthetic auxin herbicides are provided. These half salts are useful for controlling unwanted plant growth. The half salts have low solubility in water, low volatility relative to commercial compositions of the corresponding synthetic auxin herbicides, and offer comparable herbicidal performance when compared to existing salts of the synthetic auxin herbicides.Type: GrantFiled: March 9, 2017Date of Patent: January 7, 2020Assignee: Dow AgroSciences LLCInventors: Lei Liu, Holger Tank, Melissa Gail Olds, Stephen L. Wilson
-
Patent number: 10526272Abstract: An object of the present invention is to provide a method for efficiently eliminating water from a composition containing an acrylic acid derivative and water. This problem is solved by a method for eliminating water from a composition A containing: (A) an acrylic acid derivative represented by Formula (I): wherein R1 and R2 are identical or different, and each represents alkyl, fluoroalkyl, aryl that may have one or more substituents, halogen, or hydrogen, R3 represents alkyl, fluoroalkyl, aryl that may have one or more substituents, or hydrogen, and X represents alkyl, fluoroalkyl, halogen, or hydrogen; and (B) water, the method comprising step A of bringing the composition A into contact with a zeolite.Type: GrantFiled: August 5, 2016Date of Patent: January 7, 2020Assignee: DAIKIN INDUSTRIES, LTD.Inventors: Makoto Matsuura, Yosuke Kishikawa, Asako Yoshiyama, Sumi Ishihara
-
Patent number: 10526273Abstract: Disclosed herein are surfactant compounds, that are surface active, liquid, chiral, and micelle forming. Also disclose herein are ionic liquids and compsitions comprising the surfactant compounds.Type: GrantFiled: January 24, 2019Date of Patent: January 7, 2020Assignee: Vanderbilt UniversityInventors: Prasad L. Polavarapu, Vijay Raghavan
-
Patent number: 10526274Abstract: Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.Type: GrantFiled: May 31, 2018Date of Patent: January 7, 2020Assignee: INSMED INCORPORATEDInventors: Vladimir Malinin, Walter Perkins, Franziska Leifer, Donna Konicek, Zhili Li, Adam Plaunt
-
Patent number: 10526275Abstract: Systems and method are provided for reducing the water content in ethanolamine product streams from approximately 0.15%-0.19% by weight of water to approximately 0.02 to approximately 0.04 by weight of water. The reduced water content can be achieved by increasing the processing conditions at the monoethanolamine column by approximately 5% to approximately 20%, more preferably to approximately 10%, and by adding a dummy stream to the monoethanolamine column, which can be recycled to the reactor. The increased processing conditions and dummy stream at the monoethanolamine column can result in the following to achieve said water content: (i) the bottom stream flow rate increase by up to approximately 18.9%; the reboiler duty can be increased by up to 47.9%; and (iii) the condenser duty can be increased by up to approximately 52.5%.Type: GrantFiled: April 6, 2015Date of Patent: January 7, 2020Assignee: SABIC GLOBAL TECHNOLOGIES B.V.Inventor: Naeem Al-Hazmi
-
Patent number: 10526276Abstract: The present invention relates to a group of compounds with a structural nucleus derived from phenylacetamide, having the following formula (I): that can modulate the DREAM neuronal calcium sensor. Consequently, the present invention also relates to the use of these compounds for the treatment or prevention of disorders or diseases in which DREAM levels are above or below physiologically normal levels.Type: GrantFiled: December 17, 2015Date of Patent: January 7, 2020Assignees: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS, CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES NEURODEGENERATIVAS (CIBERNED), UNIVERSIDAD AUTÓNOMA DE MADRIDInventors: Marta Gutiérrez Rodríguez, Pilar Cercos Pita, María Rosario Herranz Herranz, María Teresa García López, María Carmen Valenzuela Miranda, José Ramón Naranjo Orovio, Britt Mellstrom, Paz González Pérez, María Mercedes Martín Martínez, José Manuel Dopazo Santos
-
Patent number: 10526277Abstract: Di(amido(alkyl)phenol) compounds and upgraded molecular weight polymers made from such compounds have particular utility in coating compositions, especially for use on food and beverage contact substrates that are formed into or will be formed into containers or container components.Type: GrantFiled: October 16, 2014Date of Patent: January 7, 2020Assignee: SWIMC LLCInventors: Sebastien Gibanel, Benoit Prouvost, Bernard Boutevin
-
Patent number: 10526278Abstract: Modulation of quorum sensing in Gram-negative bacteria, particularly strains of Pseudomonas which form biofilms, by compounds including those of formula I and formula II: where: AR is optionally substituted phenyl, cycloalkyl or cycloalkenyl or heterocyclic, and R1 is optionally substituted alkyl, alkenyl, alkoxyalkyl, or alkylthioalkyl or alkyl substituted at the omega position with optionally substituted phenyl, cyclohexyl or cyclohexenyl. In particular compounds inhibit quorum sensing and biofilm formation. Pharmaceutical compositions for treatment of bacterial infections and methods of treatment of such infections are provided.Type: GrantFiled: October 11, 2018Date of Patent: January 7, 2020Assignee: Wisconsin Alumni Research FoundationInventors: Helen Blackwell, Daniel Manson
-
Patent number: 10526279Abstract: The present invention provides a process for the preparation of Teriflunomide (Formula-I). The present invention describes the synthesis of Teriflunomide without isolating the intermediate Leflunomide. Teriflunomide is prepared from 5-Methyl isoxazole-4-carboxylic acid by converting to its acid chloride and coupling with 4-trifluoromethyl aniline to obtain Leflunomide (which is not isolated) followed by ring opening reaction using aq. Sodium Hydroxide to form Teriflunomide. In other words, the process is telescoped from 5-methylisoxazole-4-carbonyl chloride.Type: GrantFiled: June 16, 2016Date of Patent: January 7, 2020Assignee: BIOCON LIMITEDInventors: Venkata Raghavendracharyulu Palle, Ramakrishna Parameshwar Bhat, Mariappan Kaliappan, Jithendra R. Babu, Rajmahendra Shanmughasamy
-
Patent number: 10526280Abstract: A compound, or pharmaceutically acceptable salt thereof, having a formula I of: wherein R1 is H or optionally-substituted alkyl; R2 is optionally-substituted alkyl; R3 and R4 are each independently H or optionally-substituted alkyl; R5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R6 and R7 are each independently H, deuterium, optionally-substituted alkyl, or R6 and R7 together form a carbocyclic; R8 is optionally-substituted thiazolyl, optionally-substituted thiophenyl, or substituted phenyl, provided that if R8 is 4-halophenyl, then R2 is substituted alkyl or branched alkyl or at least one of R6 or R7 is not H; and R30, R31 and R32 are each independently H, deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy.Type: GrantFiled: November 13, 2015Date of Patent: January 7, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Peter Wipf, Athanassios Tzounopoulos
-
Patent number: 10526281Abstract: Disclosed is a novel method of controlling the formation of biuret in urea production, and particularly reducing, preventing or reversing such formation. This is accomplished by adding liquid ammonia to a urea aqueous stream. This addition is done at one or more positions downstream of a recovery section in a urea plant. The addition of liquid ammonia serves to shift the equilibrium of biuret formation from urea, to the side of the formation of urea from biuret and ammonia. The invention can be accomplished also in pre-existing urea plant, by the simple measure of providing an appropriate inlet for liquid ammonia, in fluid communication with a source of such liquid ammonia.Type: GrantFiled: April 28, 2017Date of Patent: January 7, 2020Assignee: STAMICARBON B.V.Inventor: Eelco Mostert
-
Patent number: 10526282Abstract: The present specification relates to a fluorine-based compound for a brancher, a polymer using the same, a polymer electrolyte membrane using the same, a fuel cell using the same, and a redox flow battery including the same.Type: GrantFiled: October 28, 2015Date of Patent: January 7, 2020Assignee: LG CHEM, LTD.Inventors: Hyun Woog Ryu, Sehee Jung, Joong Jin Han, Yong Jin Jang, Youngjea Kim, Esder Kang
-
Patent number: 10526283Abstract: Provided are mucolytic compounds that are more effective, and/or absorbed less rapidly from mucosal surfaces, and/or are better tolerated as compared to N-acetylcysteine (NAC) and DTT. The compounds are represented by compounds of Formula I which embrace structures (Ia)-(Ib): where the structural variables are as defined herein.Type: GrantFiled: May 2, 2016Date of Patent: January 7, 2020Assignee: PARION SCIENCES, INC.Inventors: Michael Ross Johnson, William R. Thelin
-
Patent number: 10526284Abstract: What is described is a compound of formula I consisting of a compound in which R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L1 and L2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 20, 2017Date of Patent: January 7, 2020Assignee: ARCTURUS THERAPEUTICS, INC.Inventors: Joseph E. Payne, Padmanabh Chivukula, Priya Karmali, Steven P. Tanis
-
Patent number: 10526285Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: GrantFiled: October 2, 2018Date of Patent: January 7, 2020Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.Inventors: Jean-Christophe Andrez, Philippe Bergeron, Paul Robert Bichler, Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Wei Gong, Michael Edward Grimwood, Abid Hasan, Ivan William Hemeon, Qi Jia, Brian Salvatore Safina, Shaoyi Sun, Michael Scott Wilson, Alla Yurevna Zenova
-
Patent number: 10526286Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.Type: GrantFiled: June 4, 2018Date of Patent: January 7, 2020Assignee: AstraZeneca ABInventors: Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg, Sarah Lever
-
Patent number: 10526287Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.Type: GrantFiled: April 22, 2016Date of Patent: January 7, 2020Assignee: Constellation Pharmaceuticals, Inc.Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Côté, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Rishi G. Vaswani
-
Patent number: 10526288Abstract: The object of the present invention is to provide a method for preparing 4-(piperidin-4-yl)morpholine, which is easy to operate. The object can be solved by a method for preparing 4-(1-benzylpiperidin-4-yl)morpholine, characterized in that 5-fold molar or more of morpholine is added to 1-benzyl-4-piperidone, and the mixture is reacted with hydrogen under 1 MPa or less in the presence of platinum catalyst or palladium catalyst.Type: GrantFiled: June 9, 2017Date of Patent: January 7, 2020Assignee: YUKI GOSEI KOGYO CO., LTD.Inventors: Hiromi Ishikawa, Kiyono Nakagawa, Yukiko Takeda
-
Patent number: 10526289Abstract: The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.Type: GrantFiled: August 22, 2017Date of Patent: January 7, 2020Assignee: Northwestern UniversityInventors: Richard B. Silverman, Yinan Zhang
-
Patent number: 10526290Abstract: The present invention relates to bendamustine derivatives and related compounds of formula (VII), (VIII) and (IX), and medical uses thereof in particular in cancer therapy.Type: GrantFiled: June 14, 2013Date of Patent: January 7, 2020Assignee: SYNBIAS PHARMA AGInventors: Helmut Schickaneder, Christian Schickaneder, Armin Buschauer, Stefan Huber, Michael Limmert, Günther Bernhardt, Mathias Lubbe, Harald Hofmeier
-
Patent number: 10526291Abstract: Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.Type: GrantFiled: October 22, 2018Date of Patent: January 7, 2020Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence, Gary W. Reuther
-
Patent number: 10526292Abstract: Sodium channel blockers represented by the formula: are provided where the structural variables are defined herein. The invention also includes a variety of compositions, combinations and methods of treatment using these inventive sodium channel blockers.Type: GrantFiled: December 20, 2017Date of Patent: January 7, 2020Assignee: Parion Sciences, Inc.Inventors: Michael Ross Johnson, William Robert Thelin, Richard C. Boucher
-
Patent number: 10526293Abstract: This method for producing a fullerene derivative is a method for producing a fullerene derivative having a partial structure shown by formula (1) by reacting a predetermined halogenated compound and two carbon atoms adjacent to each other for forming a fullerene skeleton in a mixed solvent of an aromatic solvent and an aprotic polar solvent having a C?O or S?O bond in the presence of at least one metal selected from the group comprising manganese, iron, and zinc; (in formula (1), C* are each carbon atoms adjacent to each other for forming a fullerene skeleton, A is a linking group having 1-4 carbon atoms for forming a ring structure with two C*, in which a portion thereof may be a substituted or condensed group).Type: GrantFiled: September 4, 2015Date of Patent: January 7, 2020Assignees: SHOWA DENKO K.K., MITSUBISHI CORPORATIONInventors: Tienan Jin, Weili Si, Yoshinori Yamamoto, Takeshi Igarashi
-
Patent number: 10526294Abstract: The present disclosure relates generally to derivatives of pyrrolobenzodiazepines and antibody-drug conjugates thereof and to methods of using these conjugates as therapeutics and/or diagnostics.Type: GrantFiled: June 22, 2017Date of Patent: January 7, 2020Assignee: Mersana Therapeutics, Inc.Inventors: Joshua D. Thomas, Mao Yin, Aleksandr V. Yurkovetskiy, Patrick R. Conlon, Ahmed Hilmy, Eugene W. Kelleher, Timothy B. Lowinger, Cheri A. Stevenson, Shuyi Tang
-
Patent number: 10526295Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.Type: GrantFiled: December 30, 2016Date of Patent: January 7, 2020Assignee: Karyopharm Therapeutics Inc.Inventor: Erkan Baloglu
-
Patent number: 10526296Abstract: Described are high energy light blocking compounds and ophthalmic devices containing the compounds. In particular, described are hydroxyphenyl naphthotriazole structures with polymerizable functionality that block high energy light and are visibly transparent. The hydroxyphenyl naphthotriazole structures can be incorporated into ophthalmic devices, such as hydrogel contact lenses, to protect eyes from high energy light radiation.Type: GrantFiled: May 15, 2018Date of Patent: January 7, 2020Assignee: Johnson & Johnson Vision Care, Inc.Inventors: Shivkumar Mahadevan, Leilani K. Sonoda, Dola Sinha, Patricia Martin
-
Patent number: 10526297Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein R1 is alkyl, Cl, F or Br, R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups R6 is selected from R7, OR7 and NR8R6; R7R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocycyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN NO1, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy, X and Z are each independently CR11 and Y is selected from CR11 and N and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.Type: GrantFiled: August 31, 2018Date of Patent: January 7, 2020Assignees: InFlectis BioScience, United Kingdom Research and InnovationInventors: Philippe Guedat, Anne Bertolotti
-
Patent number: 10526298Abstract: Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and nonalcoholic steatohepatitis (NASH); ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.Type: GrantFiled: June 18, 2018Date of Patent: January 7, 2020Assignee: EPIGEN BIOSCIENCES, INC.Inventors: Graham Beaton, Fabio C. Tucci, Satheesh B. Ravula, Chandravadan R. Shah, Hiep Luu
-
Patent number: 10526299Abstract: An apparatus includes a conduit with two process fluid inlets at one end of the conduit, one process fluid outlet at an opposing end, a heat exchange medium inlet, and a heat exchange medium outlet. One of the fluid inlets includes a tube extending into the conduit and a perforated node at the end of the tube, and the other of the fluid inlets is arranged up stream of the perforated node. The apparatus further includes hollow tubes positioned longitudinally within the conduit between the two process fluid inlets, the process fluid outlet, the heat exchange medium inlet and the heat exchange medium outlet. In addition, the apparatus includes a collection vessel positioned proximate the fluid outlet and fibers extending through each of the hollow tubes, wherein one end of the fibers is secured to the perforated node and the other end of the fibers extends into the collection vessel.Type: GrantFiled: August 5, 2019Date of Patent: January 7, 2020Assignee: Chemtor, LPInventor: John Lee Massingill
-
Patent number: 10526300Abstract: Processes for reducing the amount of a gaseous iodide-containing impurity present in a recycle gas stream used in the production of ethylene oxide, in particular alkyl iodide and vinyl iodide impurities, are provided. Processes for producing ethylene oxide, ethylene carbonate and/or ethylene glycol, and associated reaction systems are similarly provided.Type: GrantFiled: December 13, 2016Date of Patent: January 7, 2020Assignee: SHELL OIL COMPANYInventors: Wayne Errol Evans, Jesse Raymond Black, Michael Francis Lemanski
-
Patent number: 10526301Abstract: Disclosed is a process to produce a purified vapor comprising dialkyl-furan-2,5-dicarboxylate (DAFD). Furan-2,5-dicarboxylic acid (FDCA) and an alcohol in an esterification zone to generate a crude diester stream containing dialkyl furan dicarboxylate (DAFD), unreacted alcohol, 5-(alkoxycarbonyl)furan-2-carboxylic acid (ACFC), and alkyl furan-2-carboxylate (AFC). The esterification zone comprises at least one reactor that has been previously used in an DMT process.Type: GrantFiled: May 10, 2019Date of Patent: January 7, 2020Assignee: Eastman Chemical CompanyInventors: Kevin John Fontenot, Mesfin Ejerssa Janka, Kenny Randolph Parker, Ashfaq Shahanawaz Shaikh
-
Patent number: 10526302Abstract: The invention relates to a process for the production of 5-hydroxymethylfurfural from a feedstock comprising at least one sugar using a combination of at least one catalyst selected from the homogeneous Lewis acids, the heterogeneous Lewis acids and the heterogeneous bases and at least one homogeneous Brønsted acid catalyst selected from the families of the thioureas, the sulphonic acids and the phosphorus-containing organic compounds, alone or in a mixture, in the presence of at least one aprotic polar solvent, at a temperature comprised between 30° C. and 300° C., and at a pressure comprised between 0.1 MPa and 10 MPa.Type: GrantFiled: October 17, 2016Date of Patent: January 7, 2020Assignee: IFP Energies NouvellesInventors: Myriam Souleymanou, Marc Jacquin, Damien Delcroix
-
Patent number: 10526303Abstract: In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as psychiatric disorders, depression, post-traumatic stress disorder, and autism spectrum disorders, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof. In certain embodiments, it is contemplated that the 7,8-substituted flavone derivatives disclosed herein are prodrugs of 7,8-dihydoxyflavone and analogs.Type: GrantFiled: February 26, 2018Date of Patent: January 7, 2020Assignee: Emory UniversityInventor: Keqiang Ye
-
Patent number: 10526304Abstract: The present invention relates to nebivolol synthesis method and intermediate compound thereof. Specifically, the present invention relates to a method for synthesizing nebivolol, intermediate compound thereof, and a method for preparing the intermediate compound.Type: GrantFiled: May 19, 2015Date of Patent: January 7, 2020Assignee: ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.Inventor: Zhiguo Zheng
-
Patent number: 10526306Abstract: A method for purifying crystals in a glass or metal container. A hydrocarbon is introduced into feed material containing tetrahydrocannabinol (THC). The feed material and hydrocarbon is placed in a glass or metal container. The hydrocarbon is then removed within a few minutes after introduction, leaving at least some hydrocarbon in the feed material. Pressure is allowed to build within the container in an oven or in a jacketed vessel for 2-3 weeks. During this time, THC acid crystals precipitate out and fall to the bottom of the container. The contents of the container are poured into a Buchner funnel and a vacuum is applied thereto in order to pull terpenes into a beaker. The terpenes are placed into an oven in order to purge off any remaining solvent. The funnel is then scraped to acquire THC acid crystals.Type: GrantFiled: April 19, 2019Date of Patent: January 7, 2020Inventors: Pratt Bethers, David Goodman, III
-
Patent number: 10526307Abstract: Disclosed are compounds, for example, compounds of formula (I), (Formula (I) wherein R, R0, R1-R8, n, X, Y, Y?, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.Type: GrantFiled: December 16, 2015Date of Patent: January 7, 2020Assignee: ADT Pharmaceuticals, LLCInventors: Gary A. Piazza, Xi Chen, Adam B. Keeton, Michael R. Boyd
-
Patent number: 10526308Abstract: The present invention regards new adipate-type compounds suitable as an intermediate in organic chemistry, a platform chemical for the production of other chemicals, and as a monomer and co-monomer useful for the preparation of polymers and copolymers. The invention also regards the process of preparing the new adipate-type compounds from bio-based raw materials such as sugars.Type: GrantFiled: May 4, 2017Date of Patent: January 7, 2020Assignee: HALDOR TOPSØE A/SInventors: Esben Taarning, Amanda Birgitte Sølvhøj
-
Patent number: 10526309Abstract: This invention is in the area of improved therapeutic combinations for and methods of treating selected cancers using selected pyrimidine compounds having pan-TAM or Mer/Axl dual receptor tyrosine kinase inhibitory activity in combination with immune checkpoint inhibitors. In one aspect, an improved treatment for select cancers is disclosed using selected pyrimidine compounds described herein in combination with an immune checkpoint inhibitor, for example, a cytotoxic T-lymphocyte-associated protein 4 (CTLA4) inhibitor, a programmed cell death protein 1 (PD1) inhibitor, or a programmed death-ligand 1 (PDL-1) inhibitor, or combination thereof.Type: GrantFiled: September 30, 2016Date of Patent: January 7, 2020Assignee: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: Xiaodong Wang, Dehui Zhang, Dmitri Kireev, Henry Shelton Earp, III
-
Patent number: 10526310Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3,4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.Type: GrantFiled: April 15, 2019Date of Patent: January 7, 2020Assignees: Aragon Pharmaceuticals Inc., Sloan Kettering Institute for Cancer ResearchInventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
-
Patent number: 10526311Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.Type: GrantFiled: September 29, 2016Date of Patent: January 7, 2020Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Gianni Chessari, Steven Howard, Ildiko Maria Buck, Benjamin David Cons, Christopher Norbert Johnson, Rhian Sara Holvey, David Charles Rees, Jeffrey David St. Denis, Emiliano Tamanini, Bernard Thomas Golding, Ian Robert Hardcastle, Celine Florence Cano, Duncan Charles Miller, Martin Edward Mäntylä Noble, Roger John Griffin, James Daniel Osborne, Joanne Peach, Arwel Lewis, Kim Louise Hirst, Benjamin Paul Whittaker, David Wyn Watson, Dale Robert Mitchell
-
Patent number: 10526312Abstract: The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.Type: GrantFiled: January 28, 2019Date of Patent: January 7, 2020Assignee: Mycovia Pharmaceuticals, Inc.Inventors: William J. Hoekstra, Robert J. Schotzinger, Stephen W. Rafferty
-
Patent number: 10526313Abstract: BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.Type: GrantFiled: May 24, 2018Date of Patent: January 7, 2020Assignee: BioAxone BioSciences, Inc.Inventors: Kenneth M. Rosen, Matthew D. Abbinanti, Joerg Ruschel, Lisa Mckerracher, Lisa Bond Moritz
-
Patent number: 10526314Abstract: The present invention relates to novel 5-(hydroxyalkyl)-1-heteroaryl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.Type: GrantFiled: May 2, 2017Date of Patent: January 7, 2020Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventors: Marie-Pierre Collin-Kröpelin, Peter Kolkhof, Thomas Neubauer, Chantal Fürstner, Elisabeth Pook, Matthias Beat Wittwer, Carsten Schmeck, Pierre Wasnaire, Hanna Tinel, Heiko Schirmer
-
Patent number: 10526315Abstract: This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention.Type: GrantFiled: June 15, 2017Date of Patent: January 7, 2020Assignee: ORION OPHTHALMOLOGY LLCInventors: Robert Gomez, Jinyue Ding, Renata Marcella Oballa, David Andrew Powell
-
Patent number: 10526316Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: October 7, 2016Date of Patent: January 7, 2020Assignee: Janssen Pharmaceutica NVInventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
-
Patent number: 10526317Abstract: Compounds useful as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.Type: GrantFiled: July 5, 2017Date of Patent: January 7, 2020Assignees: Pierce Biotechnology, Inc., Dyomics GmbHInventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Boguslawa R. Dworecki, Frank G. Lehmann, Marie Christine Nlend
-
Patent number: 10526318Abstract: Oral formulations of benzofuran compounds which modulate cannabinoid receptors are presented. Methods of using these formulations for treatment of cannabinoid receptor-mediated disease, including neuropathic pain and addition, are also described.Type: GrantFiled: January 5, 2018Date of Patent: January 7, 2020Assignee: THE CLEVELAND CLINIC FOUNDATIONInventors: Joseph Foss, Mohamed Naguib Attala
-
Patent number: 10526319Abstract: The present invention provides halogenated quinazolin-THF-amines as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.Type: GrantFiled: June 13, 2018Date of Patent: January 7, 2020Assignee: H. Lundbeck A/SInventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård
-
Patent number: 10526320Abstract: The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholangitis, dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 12, 2017Date of Patent: January 7, 2020Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.Inventors: Zhiliang Yuan, Chaofeng Long, Zhigan Jiang, Xiaoxin Chen, Haiying He, Xing Liu, Xiao Zhang, Zhiqiang Liu, Yan Wang, Leilei Gao, Zhen Gong, Jian Li, Shuhui Chen
-
Patent number: 10526321Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.Type: GrantFiled: May 15, 2018Date of Patent: January 7, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Stephen T. Wrobleski, Shuqun Lin